Vaccine Biotherapy Of Cancer: Autologous Tumor Cells and Dendritic Cells as Active Specific Immunotherapy in Patients With Metastatic Melanoma

Trial Profile

Vaccine Biotherapy Of Cancer: Autologous Tumor Cells and Dendritic Cells as Active Specific Immunotherapy in Patients With Metastatic Melanoma

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Jul 2016

At a glance

  • Drugs Eltrapuldencel-T (Primary)
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Acronyms DCVaccineMel
  • Most Recent Events

    • 07 Jun 2016 5-year follow-up results from NCT00948480 and NCT00436930 trials (n=72) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
    • 28 Jul 2009 Results have been published in the June 2009 issue of Cancer Biotherapy and Radiopharmaceuticals, according to a Hoag Memorial Hospital Presbyterian media release.
    • 01 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top